Advances in Current and Emerging Therapies for Hemophilia

Tim Boonstra, RPh, Pharmacy Manager at Fairview Center for Bleeding and Clotting Disorders, talks about new therapies for hemophilia and exciting advancements on the horizon.

Tim Boonstra, RPh, Pharmacy Manager at Fairview Center for Bleeding and Clotting Disorders, talks about new therapies for hemophilia and exciting advancements on the horizon.

Transcript

There’s been a transition from, if we use factor VIII patients as an example, most of them we’d treat 3 times a week and even some we’d recommend every other day. Now with the advent of more extended half-life products, some of them can treat as few as just once a week, which has been a big advance. There’s also the bi-specific antibodies, emiciziumab, which is now available, which patients can treat subcutaneously even once per month. And there’s even new therapies on the horizon, tissue factor pathway inhibitors and antithrombin inhibitors are also probably coming in the next couple years. And then, gene therapy, we’re starting trials for gene therapy, which could make patients not have to treat at all. So it’s very exciting for emerging therapies.

For more on hemophilia, click here.